Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 41, 5039-5043, December 1, 1981]
© 1981 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hecht, S. S.
Right arrow Articles by Young, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hecht, S. S.
Right arrow Articles by Young, R.

Metabolic {alpha}-Hydroxylation of N-Nitrosomorpholine and 3,3,5,5-Tetradeutero-N-nitrosomorpholine in the F344 Rat1,2,

Stephen S. Hecht3 and Ruth Young

Division of Chemical Carcinogenesis, American Health Foundation, Naylor Dana Institute for Disease Prevention, Valhalla, New York 10595

We studied the metabolism in the male F344 rat of N-nitrosomorpholine and of 3,3,5,5-tetradeutero-N-nitrosomorpholine; the latter is less carcinogenic and less mutagenic than is N-nitrosomorpholine. {alpha}-Hydroxylation (3- or 5-hydroxylation) of N-nitrosomorpholine by liver microsomes and a reduced nicotinamide adenine dinucleotide phosphate-generating system produced (2-hydroxyethoxy)acetaldehyde, which was identified as its 2,4-dinitrophenylhydrazone derivative. When we administered N-nitrosomorpholine to rats i.p., we did not detect (2-hydroxyethoxy)acetaldehyde in the urine, but we did identify (2-hydroxyethoxy)acetic acid (16% of the dose). We also identified N-nitroso(2-hydroxyethyl)glycine (33% of the dose) from ß-hydroxylation (2- or 6-hydroxylation), N-nitrosodiethanolamine (12%), and unchanged N-nitrosomorpholine (1.5%) in the urine. The deuterated analogs of the above metabolites were isolated from the urine of rats treated with 3,3,5,5-tetradeutero-N-nitrosomorpholine in yields as follows: (2-hydroxyethoxy)acetic acid (3.4%); N-nitroso(2-hydroxyethyl)glycine (37%); N-nitrosodiethanolamine (12%); N-nitrosomorpholine (0.4%). These data demonstrate that deuterium substitution in the {alpha}-positions of N-nitrosomorpholine caused a decrease in the extent of {alpha}-hydroxylation and indicate that {alpha}-hydroxylation is the mechanism of activation of N-nitrosomorpholine.

1 This work was supported by National Cancer Institute Grant CA23901. This is Paper 35 of the series, "A Study of Chemical Carcinogenesis."

2 This publication is dedicated to the founder of the American Health Foundation, Dr. Ernst L. Wynder, on the occasion of the 10th anniversary of the Naylor Dana Institute for Disease Prevention.

3 To whom requests for reprints should be addressed.

Received 5/29/81. Accepted 8/ 3/81.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1981 by the American Association for Cancer Research.